CD3-binding (T cell engaging) immune stimulating antibody-based therapies |
|
Enduring |
|
$35.00 |
Assessing adversity in immunosafety (preclinical) |
|
Enduring |
|
$25.00 |
Cytokine Release Syndrome (CRS) |
|
Enduring |
|
$35.00 |
Nonclinical Development of Biologics |
|
Enduring |
|
$35.00 |
B cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities) |
|
Enduring |
|
$25.00 |
TDAR assessments |
|
Enduring |
|
$35.00 |
Animal models and species differences (immune system) |
|
Enduring |
|
$25.00 |
Immunomodulating therapies (overview) |
|
Enduring |
|
$25.00 |
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
Diversity of immune responses (impact of age, sex, pregnancy, co-morbidities, etc.) |
|
Enduring |
|
$25.00 |
Immunopathology: evaluation, assessment, and considerations |
|
Enduring |
|
$25.00 |
HESI: Human Health and Safety |
|
Enduring |
|
$0.00 |
Basic Immunology: Introduction to Immune Cells and Innate and Adaptive Immunity |
|
Enduring |
|
$25.00 |
Assessing adversity in immunosafety (preclinical) |
|
Enduring |
|
$25.00 |
T cell targeting therapies (e.g. activation, inhibition pathways, therapies, toxicities) |
|
Enduring |
|
$25.00 |